{'fraction_non_alphanumeric': 0.020181634712411706, 'fraction_numerical': 0.013118062563067608, 'mean_word_length': 5.702702702702703, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Atorvastatin and oxidative stress in coronary heart disease with obesity].

The aim of the work was to study the role of atorvastatin in the correction of oxidative stress manifestations in patients with coronary heart disease and dyslipidemnia (DLP). It included 122 patients with stable forms of CHD and 20 practically healthy subjects. Plasma lipids and products of lipid peroxidation (dienic conjugates and compounds reacting with 2-thiobarbituric acid), eryhrocyte antioxidative enzymes glutathione peroxidase and superoxide dismutase were determined by standard methods; activity of the ceruloplasmin/transferrin antioxidant system) was measured by electron paramagnetic resonance. The patients underwent 24 hr ECG Holter monitoring. Atorvastatin at a dose of 20 mg/d given during 6 months exerted antioxidative and antiperoxidative effects in 90% of the patients. It normalized parameters of lipid peroxidation and antioxidant protection thereby improving the clinical course of CHD.